Talk title Novel probiota that reduces inflammation in the entire body and stay in the guts more than 60 days
Speaker Prof. Robert H. SCHIESTL
Professor
Pathology, Environmental Health and Radiation Oncology of UCLA Schools of Medicine and Public Health
Date & Time 23 January 2019 (Wed)
10:00-11:00
Venue Room G004, E12 Building (University of Macau)
Abstract Probiotics is a booming market with about $30 billion. Probiotics will also be added to juices and yogurts. Intestinal microbiota plays a role in the nutrient metabolism, modulation of the immune system, obesity and intestinal inflammation.

We tested Atm deficient mice for genotoxicity, genetic instability, DNA damage, Inflammation markers, cancer latency and longevity and high throughput sequencing of the intestinal microbiota.

Isogenic mice from different facilities showed a four fold difference in life expectancy, a 4.5 fold difference in genetic instability and DNA damage. The onset of lymphomas was significantly 2.5 fold different. We sequenced the microbiota of both facilities and found Lactobacillus johnsonii 456 as dominant bacterial strain in the health beneficial microbiota. We isolated this bacterium. Just this bacterium by itself reduced genotoxicity, reduced levels of cytotoxic T cells, natural killer cells, CD3 cells in the liver, spleen and blood and reduced inflammatory cytokines and induced anti-inflammatory cytokines.  After gavage of mice with Lactobacillus johnsonii 456 we found that after 50 days they still had the same level in the feces than after the gavage, indicating a permanent establishment of our strain. We also found similar differences in Trp53 deficient and even in wildtype mice making this a general principle. We sequenced the DNA of our Lactobacillus johnsonii 456 strain and found 6 genes coding for mucus binding proteins. We compared this sequence with 8 other Lactobacillus johnsonii strains and found that none of the others had even one of those genes. Furthermore, we did a clinical trial with Lactobacillus johnsonii 456 with ingestion of normal humans of one billion CFUs per day for 7 days in yogurt. After 7 days all of 17 people except for one had a significantly increased level of Lactobacillus johnsonii 456 in the feces. After 30 days about half of all people still had an elevated level in their feces, as much as after 7 days. After 60 days still one third of the people had an elevated level of the bacterium in the feces indicating that in a portion of humans there might also be a permanent establishment probably aided by the 6 mucus binding proteins leading to sticking of the bacteria to the inside of the intestinal wall. Other probiotic strains are present only 1 or 2 days and at the most 7 days after ingestion. Our strain is unique amongst all probiotic strains that it can survive and proliferate in the human intestines.

We have shown that the Intestinal microbiota is responsible for differences in genetic instability, genotoxicity, DNA damage, inflammation, latency of lymphoma and longevity. The underlying mechanisms is due to inflammation promotion or suppression mediated by the intestinal microbiota. The understanding of this effect may lead to a breakthrough in the understanding of the causes of carcinogenesis, which might lead to prevention of AT, a currently incurable progressive disease and possibly other cancer-prone DNA repair deficient diseases or even wildtype mice and people. Other inflammation caused diseases that could be prevented are all cancers, neurodegenerative diseases, heart disease, Crohns disease, Lupus, inflammable bowel disease, ulcerative colitis, Diabetes, arthritis, asthma, fibrosis, migraine, autism and ageing. We are negotiating with some companies in the probiotic capsule, juice and yogurt as well as animal food business.